2022 Continuing Education Credits

Registrants are responsible for confirming that credits earned will be accepted for their specified certification by the appropriate accrediting body.

Attendance at conference events will be verified electronically. Each attendee seeking continuing education credits/hours will need to complete an evaluation for each session attended. Your login credentials will be used to track and tabulate each attendee’s continuing education credits/hours. After the conference, certificates documenting attendance and the number of continuing education credits/hours earned will be electronically generated and emailed to all eligible attendees. Questions concerning Continuing Education Credits may be directed to meetings@aatod.org.

To access your credits, click here.

CONTINUING EDUCATION HOURS OFFE RED For a complete listing of hours offered, click here.

2022 CONTINUING EDUCATION HOURS (CEH) CREDIT

ASWB-AATOD, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB), www.aswb.org, through the Approved Continuing Education (ACE) program. The American Association for the Treatment of Opioid Dependence (AATOD) maintains responsibility for the program. ASWB Approval Period: 6/12/2022-6/12/2025. Social workers should contact their regulatory board to determine course approval. Social workers participating in this course will receive up to 34.5 (clinical or social work ethics) continuing education clock hours. Please view the Conference Program for more information on specific learning outcomes and objectives, the target audience and the number of credit hours awarded for all conference sessions from ASWB. NAADAC-AATOD is an approved single event provider with

NAADAC, provider number 62794, offering credits for counselors. NAADAC provider status expires on January 31, 2024 for the AATOD 2022 Conference for up to 34.5 CE Credits.

ADACBGA – AATOD is an approved provider with the Alcohol & Drug Abuse Certification Board of Georgia (IC&RC Affiliate), provider number 2022-09-003, offering credits for counselors.

2022 CONTINUING NURSING EDUCATION (CNE) CREDIT NEMSD-This continuing nursing education activity was approved by the Northeast Multistate Division, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

NEMSD Approver Unit has Approved Continuing Nursing Education Activity, AATOD 2022 Conference for October 30- November 3, 2022, for 34.5 Contact Hours. 2022 CONTINUING MEDICAL EDUCATION (CME) CREDIT AMA Credit Designation Statement:
The American Society of Addiction Medicine designates this live activity for a maximum of 33.50 AMA PRA

Category 1 Credit (s) rM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Society of Addiction Medicine (ASAM) and the American Association for the Treatment of Opioid Dependence, Inc. The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians. Disclosure Information
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. These policies include mitigating all relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CE Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

 

CME Committee Reviewer
Catharina Armstrong, MD, FASAM – No relevant financial disclosures
Cara A. Poland, MD, MEd, DFASAM – No relevant financial disclosures
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM – No relevant financial disclosures
Herbert L. Malinoff, MD, FACP, DFASAM – No relevant financial disclosures
Noel llogu, MD, MRCP, FASAM – No relevant financial disclosures Presenters
Aaron Greenblatt, MD – No relevant financial disclosures
Adam Lewis, JD – No relevant financial disclosures
Aditi Ringwala, MD – No relevant financial disclosures
Alain Litwin, MD, MPH – No relevant financial disclosures
Alan Nolan, LCSW – No relevant financial disclosures
Allison Thomson, MPH – No relevant financial disclosures
Ally Lor, RN, CARN – No relevant financial disclosures
Andre Jean Remy, MD – No relevant financial disclosures
Andrea Walker, MA, MPH – No relevant financial disclosures
Andrew Schreier, ICS – No relevant financial disclosures
Andrew Stone, MD – No relevant financial disclosures
Andrew Talal, MD, MPH – No relevant financial disclosures
Anita Kennedy, BS CRPA CMA – No relevant financial disclosures
Anna Stewart, MBA- No relevant financial disclosures
Annabelle (Mimi) Belcher, PhD – No relevant financial disclosures
Anne Ruble, MD, MPH – No relevant financial disclosures
Anthony Folland, BA- No relevant financial disclosures
Arthur McFarlane, MS – No relevant financial disclosures
Ashton Marra, MS – No relevant financial disclosures
Babak lmanoel, DO- No relevant financial disclosures
Beth Rutkowski, MPH – No relevant financial disclosures
Brandee Izquierdo, DPA, MPA, CPRS – No relevant financial disclosures
Brenda Davis, MSW, CASAC-T, CMA – No relevant financial disclosures
Brian Myers, MBA, MTS, CMPE – No relevant financial disclosures
Brittania Liebla, DNP – No relevant financial disclosures
Carla Carter, JD – No relevant financial disclosures
Casey Tiefenwerth, MSW – No relevant financial disclosures
Catherine Abrams, LMSW, CAC-AD, RPS – No relevant financial disclosures Charissa Patricelli, MD – No relevant financial disclosures
Chrissie Martin, LMFT, LACS, CS – No relevant financial disclosures
Christina Mazza, RPS, CPRS, CCHW – No relevant financial disclosures Christine Neeb, MD – No relevant financial disclosures
Christine Scalise, MA, LPG, LCADC – No relevant financial disclosures Colleen Flanigan, RN, MS – No relevant financial disclosures
Dana Heilman, BS, MSW, MPH – No relevant financial disclosures
Daniel Barden, MS – No relevant financial disclosures
Darren McGregor, MS, MHS, LCMFT – No relevant financial disclosures David Whitesock – Does Disclose Commonly Well (Salary/Stockholder)
Deborah Reid, JD – No relevant financial disclosures
Deena Murphy, PhD – No relevant financial disclosures
Desmond Haneef – Perry, PRS – No relevant financial disclosures
Dona Dmitrovic, MHS – No relevant financial disclosures
Ed Soffe, LCSW-C – No relevant financial disclosures
Edward Long, AB, MA, PhD – No relevant financial disclosures
Elizabeth Connolly, MPA – No relevant financial disclosures
Ellen Weber, JD – No relevant financial disclosures
Emily Hosea – No relevant financial disclosures
Eric Schwartz, MD, MBA – No relevant financial disclosures
Eric Weintraub, MD – No relevant financial disclosures
Ericka Stropka, BS – No relevant financial disclosures
Faye Taxman, PhD – No relevant financial disclosures
Filippo Della Rocca – No relevant financial disclosures
Frances McGaffey, MPP – No relevant financial disclosures
G. Malik Burnett, MD, MBA, MPH – No relevant financial disclosures
Gabrielle de la Gueronniere, JD – No relevant financial disclosures
Gina Zaccagnino, LCSW – No relevant financial disclosures
Gregory Branch, MD, MBA, CPE – No relevant financial disclosures
Heather Raley, LCPC – No relevant financial disclosures
Hedi Levine, PhD – No relevant financial disclosures
Holly Hagle, PhD – No relevant financial disclosures
James Anderson, PA-C – No relevant financial disclosures
James Yoe, PhD – No relevant financial disclosures
Jason Kletter – Does Disclose BayMark Health Services (Employment) Salary
Jeffrey Hsu, MD – No relevant financial disclosures
Jessica Blose, LMHC, SUDP, NCC, CCMHC – No relevant financial disclosures John Brooklyn, MD – No relevant financial disclosures
John Hamilton, LMFT, LADC – No relevant financial disclosures
John McCarthy, MD – No relevant financial disclosures
Jonathan Stoltman, PhD – No relevant financial disclosures
Joshua Nirella, MS – No relevant financial relationships
Julie Achtyl, MS, LMHC, Master CASAC, NCC, ACS – No relevant financial disclosures Justin Berk, MD, MPH, MBA – No relevant financial disclosures
Kate Dunn, MSN, RN, CNL – No relevant financial disclosures
Katherine Findley, PhD, MSW – No relevant financial disclosures
Kathleen Rebbert-Franklin, LCSW-C – No relevant financial disclosures
Kathryn Cates-Wessel – No relevant financial disclosures
Katie Rouse, BA – No relevant financial disclosures
Kelly Coble, LCSW-C – No relevant financial disclosures
Kenneth Stoller – Does Disclose Berkshire Biomedical LLC (Consulting)
Kenny House, LCAS, CCS – No relevant financial disclosures
Kirsten Forseth, MPH – No relevant financial disclosures
Kisha Winston-Watkins, MBA, LCSW-C – No relevant financial disclosures
Kristi O’Malley, JD – No relevant financial disclosures
Krysten Garcia, BA – No relevant financial disclosures
Larry Onate, MD – No relevant financial disclosures
Latonya Adjei-Tabi, MPA – No relevant financial disclosures
Laura Maroldo – Does Disclose- AbbVie (Consulting) & Gilead (Speakers Bureau)
Laurie Krom, MS – No relevant financial disclosures
Linda Hurley, MA – No relevant financial disclosures
Lori Canane, LADC II – No relevant financial disclosures
Marc Fishman – Does Disclose Alkermes (Consulting) (Products/Services: Extended-release naltrexone) (Consulting Fees (e.g., advisory boards), research grant) Drug Delivery LLC (Consulting) (Products/Services: naltrexone implant) (Consulting Fees (e.g., advisory boards)
Margaret Marcello, BSN, RN, PMH-BC – No relevant financial disclosures
Maria Bruni, PhD – No relevant financial disclosures
Marian Currens, CRNP – No relevant financial disclosures
Marie Stratton, CHRS – No relevant financial disclosures
Mark Kraus, MD – No relevant financial disclosures
Mark Parrino, MPA – No relevant financial disclosures
Marla Oros, RN, MS, FAAN – No relevant financial disclosures
Mary Ann Thompson – No relevant financial disclosures
Mary Keller, MA – No relevant financial disclosures
Matthew Burgan, MD – No relevant financial disclosures
Maureen O’Neill Biggs, MSW, LCSW – No relevant financial disclosures
Meaghan Elliott, BS – No relevant financial disclosures
Megan Marx, MPA, NCPRSS – No relevant financial disclosures
Michael Gordon – Does Disclose Alkermes (Other Activities) (Products/Services: Study drug (VIVITROL) donation for NIDA/NIH study)
(Honoraria, Study drug) Braeburn (Other Activities) (Products/Services: study drug (BRIXADI/BUVADIL) for NIH/NIDA funded study) (Honoraria, Study drug) MedicaSafe (Other Activities) (Products/Services: Medication dispensing device for NIH/NIDA funded study) (Honoraria, medication dispensing device)
Michael Kidorf, PhD – No relevant financial disclosures
Michael Litterer, CHES, CPS, FHELA – No relevant financial disclosures
Michael Miller – Does Disclose US WorldMeds (Consulting) (Consulting Fees (e.g., advisory boards)
Michelle Byron, LPN – No relevant financial disclosures
Michelle Lalinde – No relevant financial disclosures
Michelle Marshall – No relevant financial disclosures
Miriam Delphin-Rittmon, PhD – No relevant financial disclosures
Mishka Terplan, MD – No relevant financial disclosures
Monica White, MS, CAC-AD, RPS – No relevant financial disclosures
Nancy Young, PhD – No relevant financial disclosures
Nicholas Van Dyke – Does Disclose BayMark Health Services (Employment)(Products/Services: Employee of company) (Salary) Nicole Augustine, MPH, MCHES, PS – No relevant financial disclosures
Patricia Precin, PhD – No relevant financial disclosures
Patti Juliana, PhD – No relevant financial disclosures
Rahul Gupta, MD, MPH, MBA, FACP – No relevant financial disclosures
Rebecca Trott, LCSW-C – No relevant financial disclosures
Rebekah Joab, JD – No relevant financial disclosures
Regina Gullette, PhD, LICDC-CS, MAC, SAP – No relevant financial disclosures
Robert Kent, JD – No relevant financial disclosures
Robin Rickard, JD – No relevant financial disclosures
Rosemarie Martin, PhD – No relevant financial disclosures
Ryan Mueller, MEd, LPC, LAC – No relevant financial disclosures
Sadie Smith, MSW – No relevant financial disclosures
Salima Montes, LCPC, CAC-AD – No relevant financial disclosures
Sara Gefvert, CRS/CPS, CMA – No relevant financial disclosures
Sarah Sweeney, MSW, MPH – No relevant financial disclosures
Shani Litwin, BA – No relevant financial disclosures
Sharif Nankoe, MD, MPA, MA, FASAM – No relevant financial disclosures
Sika Yeboah-Sampang, JD – No relevant financial disclosures
Steve Millette, MS – No relevant financial disclosures
Susan Hadley, MD – No relevant financial disclosures
Suzanne Borys, EdD – No relevant financial disclosures
Tara Kunkel, MSW – No relevant financial disclosures
Teri Morgan-Urie, CADCII – No relevant financial disclosures
Theresa Tassey, MD, MPH, MS – No relevant financial disclosures
Tina Masai – No relevant financial disclosures
Tracy Agee, NP – No relevant financial disclosures
Tracy Desruisseaux, LADC-1 – No relevant financial disclosures
Tracy Schulden, LCSW-C – No relevant financial disclosures
Tyrell Moyd, RPS, RCP- No relevant financial disclosures
Vanessa Baaklini, MSW – No relevant financial disclosures
Vickie Walters, LCSW-C – No relevant financial disclosures
Vinay Parekh, MD – No relevant financial disclosures
Yehoshua Mirkin – No relevant financial disclosures
Yngvild Olsen, MD, MPH – No relevant financial disclosures

Planning Committee
Kenneth Stoller, MD – Does disclose Berkshire Biomedical LLC (Consultant)
Susan A. Storti, PhD, RN, NEA-BC, CARN-AP – No relevant financial disclosures Holly Broce, MHA, LCADC – No relevant financial disclosures
Antoinette (Toni) Maynard-Carter – No relevant financial disclosures
Michael Rizzi – No relevant financial disclosures
Vickie L. Walters, LCSW-C – No relevant financial disclosures
Marian Currens CRNP Director – No relevant financial disclosures
Lillian Dannard, LCSW-C – No relevant financial disclosures
Robert C. Lambert, MA – No relevant financial disclosures
Barry Page – No relevant financial disclosures
Maria Ramos, CMP – No relevant financial disclosures
Brent Schwartz – No relevant financial disclosures
Tomell Harbison – No relevant financial disclosures
Mark W. Parrino, MPA – No relevant financial disclosures
Carleen Maxwell-Taylor – No relevant financial disclosures
Angelina Budija – No relevant financial disclosures
Sabrina Jones – No relevant financial disclosures

@aatod1984
  • Patient access to OTPs saves lives every day.

AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. 

Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
  • Lev Facher represented a fair reporting of the current #methadone policy debate that took place at last week’s #STATSummit. 

“Mark Parrino, AATOD’s founder and president, cautioned during the panel that achieving sweeping change might not be so easy. The health system, he argued, is unprepared and even unwilling to make methadone a part of primary care. Potential obstacles, he said, include doctors’ lack of enthusiasm about prescribing methadone; pharmacists’ unwillingness to stock and dispense it; and drug manufacturers’ reluctance to manufacture and distribute it more widely, especially following the lawsuits and criticism many have experienced in the wake of the opioid crisis and the prescription opioid oversupply that accelerated it.” #morethanmedicine #opioidusedisorder #OpposetheMOTAA 

Read More ➡️ bit.ly/3tKb1gy
  • Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. 

This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery.

Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1

For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
  • Join OKATOD, one of AATOD’s state chapters, in Oklahoma City on Oct 12 as they convene their ninth annual OKATOD Conference. This year’s theme is HARM REDUCTION: A TRANSFORMATIVE APPROACH. 

Speakers include Mark Parrino (AATOD President), Maia Szalavitz, Teresa Stephensen, Dr. Larry Lovelace, Angela Harnden, Shajine Blake, and Jason Hall. 

Register ➡️ bit.ly/461CkkG
  • Final Opportunity to Submit Proposals for the #aatod2024 Conference. The submission window will close tonight at 12am ET.

To submit a proposal, please follow the on-screen instructions, bit.ly/3KxQSzU. For questions or additional information regarding the Call for Presentations, please send an email to meetings@aatod.org or call 856-423-3091.

We look forward to receiving your submissions and hope to see you at the conference for what will be the premier conference on the treatment of opioid use disorders in 2024! #morethanmedicine #programnotapill #opioids #OUD #OpioidUseDisorder #submitproposal
  • Today is the Final Day to Submit Proposals for the #aatod2024 conference, 9/21 ➡️ bit.ly/3KxQSzU

The Workshop Committee encourages you to submit proposals on innovative initiatives to enhance patient outcomes, improve program development and administration, promote integration across the continuum of care, and the development of collaborations with organizations outside of the traditional opioid treatment system.

Conference Objectives:
1️⃣Conduct a comprehensive review of the latest evidence addressing the opioid epidemic and its implications for patients, clinicians, administrators, and policy makers by identifying the most effective interventions.
2️⃣Discuss peer to peer approaches in treating opioid use disorder in an effort to improve patient outcomes in health systems, organizations, and communities.
3️⃣Evaluate the gaps in current services for opioid use disorder and develop recommendations to improve the delivery of multidisciplinary care in various populations based upon evidence-based practices.
4️⃣Disseminate a comprehensive plan of innovative services designed to treat emerging needs of patients with opioid use disorder and improve patient outcomes by providing examples of effective methods and how to implement them.
5️⃣Identify effective referral pathways to other health services offering treatment for conditions associated with opioid use disorder addiction and/or recovery by developing partnerships within the community.
  • We are pleased to announce that the deadline for submitting presentations for the #aatod2024 Conference has been extended to Thursday, September 21, 2023.

We encourage all interested parties to take advantage of this opportunity and submit their proposals as soon as possible. We look forward to receiving your proposals and to seeing you in Las Vegas in 2024. 

https://conta.cc/3PiV5ck
  • August 31st is International Overdose Awareness Day 
💜 #IOAD2023 
💜 #NaloxoneSavesLives 
💜 #EndOverdoseNow

Please contact your State Opioid Treatment Authority for locations in your community that distribute naloxone kits —> bit.ly/3qVPOPz. 

 Full Video 🎥 bit.ly/3ElzdYD
  • Research shows methadone maintenance is more effective when it includes counseling—and even more so with medical or psychosocial services, like employment or family assistance. This is a key piece of #MAT for #OUD. More info: https://lnkd.in/ehYFCRvu 
#PNAP #ProgramNotaPill
  • Quick Reminder - Our committee deadline for #aatod2024 Conference related presentations is fast approaching on Monday, September 18th. We are encouraging you to submit your presentations since it will certainly contribute to an information-packed conference event.
Patient access to OTPs saves lives every day.

AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. 

Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
Patient access to OTPs saves lives every day. AATOD has been working with policymakers and regulatory authorities to increase access to opioid treatment programs (OTPs) though the expansion of mobile vans and Medication Assisted Treatment in correctional facilities in the United States. Please support AATOD's mission by making an online donation ➡️ https://bit.ly/3uDOeDC #givingtuesday
1 week ago
View on Instagram |
1/10
Lev Facher represented a fair reporting of the current #methadone policy debate that took place at last week’s #STATSummit. 

“Mark Parrino, AATOD’s founder and president, cautioned during the panel that achieving sweeping change might not be so easy. The health system, he argued, is unprepared and even unwilling to make methadone a part of primary care. Potential obstacles, he said, include doctors’ lack of enthusiasm about prescribing methadone; pharmacists’ unwillingness to stock and dispense it; and drug manufacturers’ reluctance to manufacture and distribute it more widely, especially following the lawsuits and criticism many have experienced in the wake of the opioid crisis and the prescription opioid oversupply that accelerated it.” #morethanmedicine #opioidusedisorder #OpposetheMOTAA 

Read More ➡️ bit.ly/3tKb1gy
Lev Facher represented a fair reporting of the current #methadone policy debate that took place at last week’s #STATSummit. “Mark Parrino, AATOD’s founder and president, cautioned during the panel that achieving sweeping change might not be so easy. The health system, he argued, is unprepared and even unwilling to make methadone a part of primary care. Potential obstacles, he said, include doctors’ lack of enthusiasm about prescribing methadone; pharmacists’ unwillingness to stock and dispense it; and drug manufacturers’ reluctance to manufacture and distribute it more widely, especially following the lawsuits and criticism many have experienced in the wake of the opioid crisis and the prescription opioid oversupply that accelerated it.” #morethanmedicine #opioidusedisorder #OpposetheMOTAA Read More ➡️ bit.ly/3tKb1gy
2 months ago
View on Instagram |
2/10
Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. 

This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery.

Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1

For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. 

This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery.

Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1

For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
Earn up to 6 LADC & LPC CEU’s at 9th Annual OKATOD Conference, which is convening this Thursday, Oct 12th in Oklahoma City. This year, the focus turns to the paramount theme of #harmreduction and its profound role in ushering transformative pathways to #recovery. Registration is now officially open, and you can secure your tickets promptly ➡️ bit.ly/45l3mm1 For more information, please visit www.okatod.org or send an email to a_rios@oktreatment.com.
2 months ago
View on Instagram |
3/10
Join OKATOD, one of AATOD’s state chapters, in Oklahoma City on Oct 12 as they convene their ninth annual OKATOD Conference. This year’s theme is HARM REDUCTION: A TRANSFORMATIVE APPROACH. 

Speakers include Mark Parrino (AATOD President), Maia Szalavitz, Teresa Stephensen, Dr. Larry Lovelace, Angela Harnden, Shajine Blake, and Jason Hall. 

Register ➡️ bit.ly/461CkkG
Join OKATOD, one of AATOD’s state chapters, in Oklahoma City on Oct 12 as they convene their ninth annual OKATOD Conference. This year’s theme is HARM REDUCTION: A TRANSFORMATIVE APPROACH. Speakers include Mark Parrino (AATOD President), Maia Szalavitz, Teresa Stephensen, Dr. Larry Lovelace, Angela Harnden, Shajine Blake, and Jason Hall. Register ➡️ bit.ly/461CkkG
3 months ago
View on Instagram |
4/10
Final Opportunity to Submit Proposals for the #aatod2024 Conference. The submission window will close tonight at 12am ET. To submit a proposal, please follow the on-screen instructions, bit.ly/3KxQSzU. For questions or additional information regarding the Call for Presentations, please send an email to meetings@aatod.org or call 856-423-3091. We look forward to receiving your submissions and hope to see you at the conference for what will be the premier conference on the treatment of opioid use disorders in 2024! #morethanmedicine #programnotapill #opioids #OUD #OpioidUseDisorder #submitproposal
3 months ago
View on Instagram |
5/10
Today is the Final Day to Submit Proposals for the #aatod2024 conference, 9/21 ➡️ bit.ly/3KxQSzU The Workshop Committee encourages you to submit proposals on innovative initiatives to enhance patient outcomes, improve program development and administration, promote integration across the continuum of care, and the development of collaborations with organizations outside of the traditional opioid treatment system. Conference Objectives: 1️⃣Conduct a comprehensive review of the latest evidence addressing the opioid epidemic and its implications for patients, clinicians, administrators, and policy makers by identifying the most effective interventions. 2️⃣Discuss peer to peer approaches in treating opioid use disorder in an effort to improve patient outcomes in health systems, organizations, and communities. 3️⃣Evaluate the gaps in current services for opioid use disorder and develop recommendations to improve the delivery of multidisciplinary care in various populations based upon evidence-based practices. 4️⃣Disseminate a comprehensive plan of innovative services designed to treat emerging needs of patients with opioid use disorder and improve patient outcomes by providing examples of effective methods and how to implement them. 5️⃣Identify effective referral pathways to other health services offering treatment for conditions associated with opioid use disorder addiction and/or recovery by developing partnerships within the community.
3 months ago
View on Instagram |
6/10
We are pleased to announce that the deadline for submitting presentations for the #aatod2024 Conference has been extended to Thursday, September 21, 2023. We encourage all interested parties to take advantage of this opportunity and submit their proposals as soon as possible. We look forward to receiving your proposals and to seeing you in Las Vegas in 2024. https://conta.cc/3PiV5ck
3 months ago
View on Instagram |
7/10
August 31st is International Overdose Awareness Day 💜 #IOAD2023 💜 #NaloxoneSavesLives 💜 #EndOverdoseNow Please contact your State Opioid Treatment Authority for locations in your community that distribute naloxone kits —> bit.ly/3qVPOPz. Full Video 🎥 bit.ly/3ElzdYD
3 months ago
View on Instagram |
8/10
Research shows methadone maintenance is more effective when it includes counseling—and even more so with medical or psychosocial services, like employment or family assistance. This is a key piece of #MAT for #OUD. More info: https://lnkd.in/ehYFCRvu 
#PNAP #ProgramNotaPill
Research shows methadone maintenance is more effective when it includes counseling—and even more so with medical or psychosocial services, like employment or family assistance. This is a key piece of #MAT for #OUD. More info: https://lnkd.in/ehYFCRvu #PNAP #ProgramNotaPill
3 months ago
View on Instagram |
9/10
Quick Reminder - Our committee deadline for #aatod2024 Conference related presentations is fast approaching on Monday, September 18th. We are encouraging you to submit your presentations since it will certainly contribute to an information-packed conference event.
4 months ago
View on Instagram |
10/10

For this #GIVINGTUESDAY, please consider making a tax-deductible gift to AATOD, so that we can continue to expand access to quality #OUD treatment services, which has been our hallmark since 1984.
DONATE --> http://bit.ly/3uDOeDC
Patient access to #OTPs saves lives every day.

Load More...

2024 Conference Las Vegas

2024 Conference

AATOD, Inc.
225 Varick Street, Suite 402
New York, New York 10014

Contact Us
Phone : 212-566-5555
Email : info@aatod.org

Social Sharing
RSS
Follow by Email
Facebook
Twitter
YouTube
LinkedIn
Instagram

Stay Connected to AATOD